Multiple administrations of Affitope PD01A, an investigational vaccine for Parkinson’s disease, elicit a safe and sustained immune response against alpha-synuclein — a protein involved in the development of Parkinson’s — in patients at the early stages of the disease, according to results from a Phase 1…

Seelos Therapeutics announced it is beginning, earlier than expected, a preclinical study into its investigational gene therapy candidate for Parkinson’s disease called SLS-004. The exact nature of this early research work was not detailed in a press release. Nerve cell damage in Parkinson’s is caused by the buildup of toxic forms…

Researchers have developed short gene promoters — structures that act like switches to turn on genes — that may boost the effectiveness of gene therapies targeting the central nervous system. These promoters allow for the delivery of larger genes into the central nervous system while keeping them active for…

Nitrome Biosciences has raised $38 million in Series A financing to advance its lead program toward clinical trials for Parkinson’s disease (PD) and other age-related disorders. “This financing will enable Nitrome to advance our mission of impacting the lives of patients with neurodegenerative and other age-related diseases,” said…

Mutations in a gene called ATP10B may increase the risk of developing Parkinson’s disease, a study has found. When mutated, ATP10B is no longer able to provide instructions to make a functional protein that is necessary to transport a fatty substance — known…

A probiotic strain of the bacteria Bacillus subtilis called PXN21 can prevent the buildup of the protein alpha-synuclein — one of the hallmarks of Parkinson’s disease — in the round worm C. elegans, researchers reports. This finding warrants further investigation to assess the therapeutic potential of dietary…

Roche presented initial data from an ongoing Phase 2 clinical trial evaluating prasinezumab (PRX002/RG7935) — an antibody against the alpha-synuclein protein — in more than 300 people with early stage Parkinson’s disease. Data highlighted that the trial’s participants, including those on MAO-B inhibitors, represent a wider population…

Delivering a gene therapy directly to the substantia nigra, an area of the brain affected by Parkinson’s disease, led to sustained protein production for up to eight years, a post-mortem of analysis of two patients revealed. The therapy’s use failed to show…

Scientists have discovered a “master controller” region that regulates aggregation of the alpha-synuclein protein, one of the distinctive features of Parkinson’s disease that is known to lead to the progressive degeneration of brain cells. Understanding how the master controller works opens new opportunities in both the…

Annovis Bio’s lead investigative therapy ANVS401 (also known as Posiphen) targeting protein buildup in the brain has been granted a U.S. patent as a way of treating Parkinson’s disease, Lewy body dementia, and other Lewy body disorders. The company, previously known as QR Pharma,…